Xi-Tao Wang

Person

Wellesley, MA, US

People

Patents Grantslast 30 patents

Information Patent Grant
Anti-IDO antibody and uses thereof
- Patent number 12,139,551
- Issue date Nov 12, 2024
- Bristol-Myers Squibb Company
- Anan Chuntharapai
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Antibodies against OX-40 and uses thereof
- Patent number 11,466,092
- Issue date Oct 11, 2022
- Bristol-Myers Squibb Company
- Zhehong Cai
- G01 - MEASURING TESTING
Information Patent Grant
Anti-GITR antibodies for cancer diagnostics
- Patent number 11,408,889
- Issue date Aug 9, 2022
- Bristol-Myers Squibb Company
- Xi-Tao Wang
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-GITR antibodies for cancer diagnostics
- Patent number 10,690,674
- Issue date Jun 23, 2020
- Bristol-Myers Squibb Company
- Xi-Tao Wang
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Antibodies against OX40 and uses thereof
- Patent number 10,683,357
- Issue date Jun 16, 2020
- Bristol-Myers Squibb Company
- Zhehong Cai
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,604,575
- Issue date Mar 31, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,584,170
- Issue date Mar 10, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,577,423
- Issue date Mar 3, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,323,092
- Issue date Jun 18, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,323,093
- Issue date Jun 18, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,316,091
- Issue date Jun 11, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,316,090
- Issue date Jun 11, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,308,714
- Issue date Jun 4, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- G01 - MEASURING TESTING
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,596
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,594
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,595
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,138,299
- Issue date Nov 27, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,072,082
- Issue date Sep 11, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 9,856,320
- Issue date Jan 2, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Antibodies against OX40 and uses thereof
- Patent number 9,644,032
- Issue date May 9, 2017
- Bristol-Myers Squibb Company
- Zhehong Cai
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Antibodies that bind PD-L1 and uses thereof
- Patent number 9,212,224
- Issue date Dec 15, 2015
- Bristol-Myers Squibb Company
- John Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240417471
- Publication date Dec 19, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240034793
- Publication date Feb 1, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- G01 - MEASURING TESTING
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240002512
- Publication date Jan 4, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTIBODIES AGAINST OX-40 AND USES THEREOF
- Publication number 20230272100
- Publication date Aug 31, 2023
- Bristol-Myers Squibb Company
- Zhehong CAI
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-CCR8 ANTIBODIES FOR TREATING CANCER
- Publication number 20230119066
- Publication date Apr 20, 2023
- Bristol-Myers Squibb Company
- Ruth Yin-Zong Lan
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-IDO ANTIBODY AND USES THEREOF
- Publication number 20210403602
- Publication date Dec 30, 2021
- Bristol-Myers Squibb Company
- Anan CHUNTHARAPAI
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS
- Publication number 20210011022
- Publication date Jan 14, 2021
- Bristol-Myers Squibb Company
- Xi-Tao WANG
- G01 - MEASURING TESTING
Information Patent Application
ANTIBODIES AGAINST OX-40 AND USES THEREOF
- Publication number 20200399385
- Publication date Dec 24, 2020
- Bristol-Myers Squibb Company
- Zhehong CAI
- G01 - MEASURING TESTING
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20200308282
- Publication date Oct 1, 2020
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190153099
- Publication date May 23, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190135920
- Publication date May 9, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190112377
- Publication date Apr 18, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190112376
- Publication date Apr 18, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190100589
- Publication date Apr 4, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190100590
- Publication date Apr 4, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190092863
- Publication date Mar 28, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180319887
- Publication date Nov 8, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180312590
- Publication date Nov 1, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180282413
- Publication date Oct 4, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180282414
- Publication date Oct 4, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180273624
- Publication date Sep 27, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTIBODIES AGAINST OX40 AND USES THEREOF
- Publication number 20180237534
- Publication date Aug 23, 2018
- Bristol-Myers Squibb Company
- Zhehong CAI
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS
- Publication number 20180164321
- Publication date Jun 14, 2018
- Bristol-Myers Squibb Company
- Xi-Tao WANG
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTIBODIES AGAINST OX40 AND USES THEREOF
- Publication number 20170306035
- Publication date Oct 26, 2017
- Bristol-Myers Squibb Company
- Zhehong CAI
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTIBODIES AGAINST OX40 AND USES THEREOF
- Publication number 20160347849
- Publication date Dec 1, 2016
- Bristol-Myers Squibb Company
- Zhehong CAI
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20160090417
- Publication date Mar 31, 2016
- Bristol-Myers Squibb Company
- JOHN P. COGSWELL
- G01 - MEASURING TESTING
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20150125463
- Publication date May 7, 2015
- Bristol-Myers Squibb Company
- John P. Cogswell
- G01 - MEASURING TESTING
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20130309250
- Publication date Nov 21, 2013
- John Cogswell
- G01 - MEASURING TESTING

Xi-Tao Wang

Person

Patents Grantslast 30 patents

Anti-IDO antibody and uses thereof

Antibodies against OX-40 and uses thereof

Anti-GITR antibodies for cancer diagnostics

Anti-GITR antibodies for cancer diagnostics

Antibodies against OX40 and uses thereof

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Antibodies against OX40 and uses thereof

Antibodies that bind PD-L1 and uses thereof

Patents Applicationslast 30 patents

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

ANTIBODIES AGAINST OX-40 AND USES THEREOF

ANTI-CCR8 ANTIBODIES FOR TREATING CANCER

ANTI-IDO ANTIBODY AND USES THEREOF

ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS

ANTIBODIES AGAINST OX-40 AND USES THEREOF

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

ANTIBODIES AGAINST OX40 AND USES THEREOF

ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS

ANTIBODIES AGAINST OX40 AND USES THEREOF

ANTIBODIES AGAINST OX40 AND USES THEREOF

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING